An interventional study of Antarctic Krill Oil and Placebo capsules in Diminished Ovarian Reserve (DOR), sponsored by Qilu Hospital of Shandong University. Not yet recruiting at 1 site in China. Open to female participants aged 30 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Qilu Hospital of Shandong University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Diminished ovarian reserve (DOR) is characterized by a reduction in the number and/or quality of remaining oocytes and may affect women's reproductive health. Antarctic krill oil contains omega-3 fatty acids, phospholipids, and other bioactive components. However, its potential effects on ovarian reserve in women with DOR remain unclear.
This study aims to evaluate the effects and safety of Antarctic krill oil supplementation in women with diminished ovarian reserve.
This is a prospective, single-center, randomized, double-blind, parallel-group controlled trial conducted at Qilu Hospital of Shandong University, China. A total of 158 women with DOR, aged 30 to 40 years, are planned to be enrolled and randomly assigned in a 1:1 ratio to receive either Antarctic krill oil or an olive oil control for 12 weeks.
The primary outcome is the change in bilateral antral follicle count (AFC) from baseline to 12 weeks. Secondary outcomes include changes in serum anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), and measures of menopausal symptoms, sleep quality, anxiety, depression, and osteoporosis risk. Safety will be assessed through adverse event monitoring and relevant laboratory examinations.
This study is expected to provide clinical evidence regarding the potential effects and safety of Antarctic krill oil supplementation in women with diminished ovarian reserve.
Diminished ovarian reserve (DOR) is a reproductive condition characterized by a reduction in ovarian follicle quantity and/or quality. It may be associated with reduced reproductive potential and changes in reproductive hormone levels. Currently, effective strategies to improve ovarian reserve remain limited, highlighting the need to investigate additional supportive interventions.
Antarctic krill oil is a marine-derived nutritional supplement containing omega-3 polyunsaturated fatty acids, phospholipids, and astaxanthin. These components have been investigated for their potential antioxidant and anti-inflammatory properties. Oxidative stress and inflammation may contribute to ovarian aging and impaired ovarian function. However, clinical evidence regarding the effects of Antarctic krill oil on ovarian reserve in women with DOR remains insufficient.
The primary objective of this study is to investigate whether 12 weeks of Antarctic krill oil supplementation improves ovarian reserve, as assessed by changes in antral follicle count (AFC), compared with an olive oil control.
The study will also evaluate changes in reproductive hormone levels, clinical symptoms, sleep quality, psychological well-being, and osteoporosis risk. Safety and tolerability will be assessed through adverse event monitoring, clinical examinations, and laboratory tests.
This prospective randomized controlled trial is designed to provide clinical evidence on the potential benefits and safety of Antarctic krill oil supplementation in women with diminished ovarian reserve.
Qilu Hospital of Shandong University is the lead sponsor of 311 studies on the registry; 188 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Serum anti-Müllerian hormone (AMH) \< 1.1 ng/mL;
Total antral follicle count (AFC) in both ovaries \< 7;
Basal follicle-stimulating hormone (FSH) ≥ 10 IU/L in two consecutive menstrual cycles.
Women aged 30-40 years.
Exclusion Criteria:
①Impaired liver or kidney function, defined as (ALT), aspartate aminotransferase (AST), serum creatinine (Cr), or blood urea nitrogen (BUN) levels exceeding 1.5 times the .
Abnormal coagulation function.
History of severe cardiovascular, cerebrovascular, immune, or metabolic diseases, or malignant tumors.
Current use of similar products or use within the previous 3 months.
Known allergy to krill oil, seafood, or any component of the placebo.
Unexplained gynecological bleeding outside the menstrual period.
Planning pregnancy, currently pregnant, or breastfeeding.
⑧Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to this group will receive Antarctic krill oil capsules (0.78 g per capsule), two capsules orally once daily for 12 weeks. Participants will also receive standardized lifestyle guidance during the study period.
Dietary Supplement: Antarctic Krill Oil
Participants assigned to this group will receive matching placebo capsules (0.78 g per capsule), two capsules orally once daily for 12 weeks. Participants will also receive standardized lifestyle guidance during the study period.
Dietary Supplement: Placebo capsules
Participants will receive Antarctic krill oil capsules (0.78 g per capsule), administered orally at a dose of two capsules once daily for 12 consecutive weeks, corresponding to a total daily dose of 1.56 g.
Also known as: Krill Oil
Participants assigned to the placebo group will receive olive oil capsules as a placebo comparator. The placebo capsules will not contain Antarctic krill oil and will be administered orally for 12 weeks according to the study protocol.
Also known as: Placebo (Olive Oil Capsules)
Change in Serum Anti-Müllerian Hormone (AMH) Levels
Serum anti-Müllerian hormone (AMH) levels will be measured at baseline and at week 12. The change in AMH levels from baseline to week 12 will be calculated and compared between the Antarctic krill oil group and the placebo control group.
Time frame: Baseline and Week 12
Change in Serum Follicle-Stimulating Hormone (FSH) Levels
Serum follicle-stimulating hormone (FSH) levels will be measured at baseline and at week 12. The change in FSH levels from baseline to week 12 will be calculated and compared between the Antarctic krill oil group and the placebo control group.
Time frame: Baseline and Week 12
Change in Antral Follicle Count (AFC)
Antral follicle count (AFC) will be assessed by transvaginal ultrasonography at baseline and at week 12. The change in AFC from baseline to week 12 will be calculated and compared between the Antarctic krill oil group and the placebo control group.
Time frame: Baseline and Week 12
Change in Serum Estradiol (E2) Levels
Serum estradiol (E2) levels will be measured at baseline and at week 12. The change in E2 levels from baseline to week 12 will be calculated and compared between the Antarctic krill oil group and the placebo control group.
Time frame: Baseline and Week 12
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Aug 2028, 20 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Krill oil
Qilu Hospital of Shandong University →